Efficacy of Alfuzosin in Male Patients with Moderate Lower Urinary Tract Symptoms: Is Metabolic Syndrome a Factor Affecting the Outcome?
CONCLUSION: Although the non-MetS patients had greater benefit from the alfuzosin therapy compared to the MetS patients, alfuzosin is an effective alpha-blocker in the treatment of MetS patients with moderate LUTS. Based on these findings, it is tempting to consider that MetS might be a negative factor for benign prostate hyperplasia treatment.
PMID: 32869259 [PubMed - as supplied by publisher]
Source: Urology Journal - Category: Urology & Nephrology Authors: Sonmez G, Topaloglu US, Keske M, Demirtas A Tags: Urol J Source Type: research
More News: Alfuzosin | Benign Prostatic Hyperplasia | Metabolic Syndrome | Statistics | Study | Urology & Nephrology